Hyperfine, Inc. Announces New Loan Agreement, Unregistered Equity Sales, and Financial Obligations

Key Highlights:

• Hyperfine, Inc. (HYPR), a Delaware-incorporated medical device company listed on Nasdaq, has entered into a Material Definitive Agreement with Horizon Technology Finance Corporation, involving a new Loan and Security Agreement dated March 18, 2026.
• The agreement creates a direct financial obligation for Hyperfine and its subsidiaries, and is accompanied by the issuance of warrants to purchase Class A common stock at \$1.20 per share.
• The warrants and underlying shares are unregistered securities offered under exemptions from registration, relying on Section 4(a)(2) of the Securities Act and/or Regulation D.
• The company has committed to registering these shares for resale, granting holders registration rights and specific protections regarding the removal of restrictive legends under certain conditions.
• No offer to sell or solicitation of an offer to buy securities is made by this filing; it is purely for disclosure purposes.

Detailed Report for Investors

1. Material Definitive Agreement: Loan and Security Agreement

Hyperfine, Inc., together with its subsidiaries Hyperfine Operations, Inc. and Liminal Sciences, Inc., has entered into a Loan and Security Agreement with Horizon Technology Finance Corporation. The precise amount of the loan is not disclosed in the summary, but the agreement is substantial enough to constitute a material definitive agreement. The agreement is filed as Exhibit 10.1.

The Loan Agreement includes various covenants and conditions typical in secured lending arrangements. Events of default under the agreement include:

• Material misrepresentations or breaches of covenants (after cure period)
• Cross-defaults with other indebtedness
• Bankruptcy and insolvency events
• Judgment defaults
• Events that could reasonably be expected to have a “material adverse effect”

If an event of default occurs, the lender may accelerate the loan, terminate commitments, increase the interest rate, and exercise other remedies.

2. Direct Financial Obligation

The new loan creates a direct financial obligation for Hyperfine. The company must comply with the financial covenants of the agreement, including maintaining a debt-to-annualized revenue ratio not greater than 1:1 immediately after loan advancement. Failure to meet these financial covenants could trigger default.

3. Unregistered Sales of Equity Securities: Warrants Issued

As part of the loan agreement, Hyperfine is issuing warrants to Horizon Technology Finance Corporation, giving the lender the right to purchase Class A common stock at \$1.20 per share. These warrants are unregistered and are offered under exemptions from the Securities Act. The underlying shares may be freely tradable under certain conditions, including the effectiveness of a registration statement or compliance with Rule 144.

Key features of the warrants:

• Cashless exercise option available.
• Adjustments to exercise price and number of shares in the event of stock splits, dividends, mergers, or reclassifications.
• Registration rights: Hyperfine will file a registration statement for resale of the shares within 60 days after the grant date, and keep it effective until shares are sold or eligible for Rule 144 resale without restrictions.
• Holder protections: Suspension periods for registration are capped (max 60 consecutive days, 120 days in any 365-day period).
• The company will bear all costs of registration, except for underwriting commissions and Holder’s counsel fees.

4. Important Shareholder Information & Price Sensitivity

Potential Share Price Impact:

• The creation of new financial obligations and dilution risk from warrant issuance are significant. If the warrants are exercised, new shares will be issued, potentially diluting existing shareholders.
• The registration rights mean the warrant holders can resell shares relatively quickly, which could increase float and put downward pressure on share price if large volumes are sold.
• Failure to comply with loan covenants or a material adverse event could lead to default, accelerating debt obligations and potentially harming the company’s financial position.
• The company’s commitment to maintaining compliance and transparency, including prompt SEC filings, may be seen as positive for governance, but the underlying financial stress is a concern.

5. Additional Details

• The warrants include detailed provisions for calculation of fair market value, anti-dilution protections, and cashless exercise mechanisms.
• Legend removal provisions and registration rights are robust, ensuring liquidity for warrant holders.
• Hyperfine’s Chief Administrative Officer, Chief Financial Officer, Treasurer, and Corporate Secretary, Brett Hale, signed the filing.
• Portions of the exhibits are omitted for confidentiality, and certain schedules are omitted as permitted by SEC regulations.

Conclusion

This 8-K filing represents a material event for Hyperfine, Inc., involving new debt, the creation of a direct financial obligation, and the issuance of unregistered equity that could dilute shareholders. The registration rights and anti-dilution protections in the warrants are investor-friendly for holders, but may introduce short-term volatility for common shareholders. Investors should monitor further disclosures and consider the potential impact on share price, especially regarding dilution and compliance with loan covenants.

Disclaimer: This article is based on information disclosed in Hyperfine, Inc.’s SEC filing dated March 18, 2026. It does not constitute investment advice or an offer to buy or sell securities. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The article is intended for informational purposes only.

View Hyperfine, Inc. Historical chart here